Source comparison
BPC-157 Typically Administered in Research: Route Comparison
Subcutaneous (SC) 200–500 mcg/kg daily Tendon repair, ligament healing, musculoskeletal injury Slow systemic absorption; peak plasma at 60–90 min; localized concentration gradient near injection site Preferred for localized tissue repair studies where proximit
This comparison does not assign a generated winner or score.
- Subcutaneous (SC)
- 200–500 mcg/kg daily
- Tendon repair, ligament healing, musculoskeletal injury
- Slow systemic absorption; peak plasma at 60–90 min; localized concentration gradient near injection site
- Preferred for localized tissue repair studies where proximity to injury site matters; most consistent route for replicability
- Intraperitoneal (IP)
- 10–1000 mcg/kg daily
- Cardiovascular protection, CNS modulation, acute systemic injury
- Rapid systemic absorption via peritoneal vasculature; peak plasma at 30–45 min
- Best for systemic effect studies; faster kinetics than SC but requires surgical skill for consistent placement
- Oral
- 10–100 mcg/kg daily
- Gastrointestinal ulcers, mucosal healing, inflammatory bowel models
- Direct mucosal contact; limited systemic bioavailability due to first-pass metabolism
- Effective only for GI-targeted outcomes; systemic bioavailability too low for musculoskeletal applications
- Topical
- 10–50 mcg/kg applied directly
- Dermal wounds, burn healing, skin regeneration
- No systemic absorption; action limited to application site
- Niche use; eliminates systemic variables but limits mechanistic interpretation to local tissue response